title: Aerosolized iloprost in CREST syndrome related pulmonary hypertension.
abstract: OBJECTIVE
  To assess the outcome of patients with CREST syndrome associated severe pulmonary hypertension treated by aerosolized iloprost in a noncomparative study.
  
  
  METHODS
  Five patients with CREST syndrome associated severe pulmonary hypertension were treated with 100 microg/day of aerosolized iloprost. New York Heart Association functional class and exercise tolerance (6 min walk test) were assessed at baseline, after one month, and then every 6 months. A right heart catheterization was performed at baseline in all but one patient. Systolic pulmonary artery pressure (PAP) was measured with Doppler echocardiography after one month and every 6 months.
  
  
  RESULTS
  The mean followup was 13.2 +/- 8.8 months (median 6, range 6-24). Subjective quality of life improved in all patients. NYHA functional class decreased from Class III to II in 3 patients, from Class III to I in one patient, and from Class IV to III in one patient. At 6 months, the distance walked in 6 min had increased from 352 +/- 48 to 437 +/- 56 m (p = 0.06). At one month the mean systolic PAP was 58 +/- 13 vs 81 +/- 9 mm Hg at baseline (p = 0.04). At 6 months the mean systolic PAP was 57 +/- 13 mm Hg (p = 0.06). The improvement of both clinical and hemodynamic status was maintained in the 2 patients treated for 2 years. Neither adverse effects nor need to increase the daily dose of iloprost were observed. One patient died of right heart failure and one patient did not experience any improvement of exercise tolerance and hemodynamics.
  
  
  CONCLUSIONS
  Aerosolized iloprost might be potentially useful as treatment for CREST syndrome associated pulmonary hypertension. However, patients who could benefit from this treatment will probably have to undergo careful criteria selection.
authors.affiliation: Department of Internal Medicine, Functional Cardiac Exploration, Regional University Hospital, Lille, France.
authors.forename: D
authors.initials: D
authors.lastname: Launay
authors.forename: E
authors.initials: E
authors.lastname: Hachulla
authors.forename: P Y
authors.initials: PY
authors.lastname: Hatron
authors.forename: L
authors.initials: L
authors.lastname: Goullard
authors.forename: T
authors.initials: T
authors.lastname: Onimus
authors.forename: S
authors.initials: S
authors.lastname: Robin
authors.forename: A L
authors.initials: AL
authors.lastname: Fauchais
authors.forename: V
authors.initials: V
authors.lastname: Queyrel
authors.forename: U
authors.initials: U
authors.lastname: Michon-Pasturel
authors.forename: M
authors.initials: M
authors.lastname: Hebbar
authors.forename: F
authors.initials: F
authors.lastname: Saulnier
authors.forename: B
authors.initials: B
authors.lastname: Devulder
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D017675:CREST Syndrome / Q000150:complications*; D004417:Dyspnea / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D016285:Iloprost / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011669:Pulmonary Wedge Pressure; D011788:Quality of Life; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D014665:Vasodilator Agents; D016285:Iloprost